Spotlight on the SAPIEN 3 transcatheter heart valve
Tobias Rheude,1 Johannes Blumenstein,2 Helge Möllmann,2 Oliver Husser2 1Department of Cardiovascular Diseases, German Heart Centre, Technical University Munich, Munich, Germany; 2Department of Cardiology, St.-Johannes-Hospital, Dortmund, Germany Abstract: Transcatheter aortic valve implanta...
Guardado en:
Autores principales: | , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0d01def058da445ba41ef4f037e34a8a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Sumario: | Tobias Rheude,1 Johannes Blumenstein,2 Helge Möllmann,2 Oliver Husser2 1Department of Cardiovascular Diseases, German Heart Centre, Technical University Munich, Munich, Germany; 2Department of Cardiology, St.-Johannes-Hospital, Dortmund, Germany Abstract: Transcatheter aortic valve implantation (TAVI) is increasingly performed in patients with severe aortic stenosis. The efficacy and safety have been demonstrated in large randomized trials in patients with high- or intermediate operative risk. With latest-generation transcatheter heart valve (THV) systems, growing operator experience and improved patient selection, clinical outcome has significantly improved with a decline of TAVI-related complications. In this review, the Edwards SAPIEN 3 THV is discussed in terms of technology, procedural advances and complication trends and future developments. Keywords: aortic valve stenosis, transcatheter aortic valve implantation, TAVI, transcatheter heart valves, Edwards SAPIEN 3 |
---|